BusinessMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive DisorderBy Nasdaq OMXDec 21, 2017, 1:00 PM UTC
BusinessMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia DisorderBy Nasdaq OMXDec 6, 2017, 1:30 PM UTC
BusinessMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive DisorderBy Nasdaq OMXSep 5, 2017, 12:00 PM UTC
BusinessMinerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With JanssenBy Nasdaq OMXAug 25, 2017, 12:30 PM UTC
BusinessMinerva Announces Amended Agreement for MIN-202 in InsomniaBy Nasdaq OMXMay 31, 2017, 8:14 PM UTC
BusinessMinerva Announces Amended Agreement for MIN-202 in InsomniaBy Nasdaq OMXMay 31, 2017, 8:14 PM UTC
BusinessMinerva Announces Amended Agreement for MIN-202 in InsomniaBy Nasdaq OMXMay 31, 2017, 8:14 PM UTC
BusinessMinerva Announces Amended Agreement for MIN-202 in InsomniaBy Nasdaq OMXMay 31, 2017, 8:14 PM UTC
